AMAG Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering

Davis Polk advised the underwriters in connection with an SEC-registered offering by AMAG Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible senior notes due 2022.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC acted as representatives of the underwriters.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families it serves.

The Davis Polk corporate team included partner Richard D. Truesdell (Picture) Jr. and associate Jeannette K. Safi. The equity derivatives team included partner Mark M. Mendez and associates Barry J. Gewolb and Hanbing Zhang. The tax team included partner Michael Farber. Associate Paul S. Lee provided intellectual property and technology advice. Counsel Ann Becchina and associate Timothy John Durbin provided ERISA advice.

Involved fees earner: Richard Truesdell – Davis Polk & Wardwell; Jeannette Safi – Davis Polk & Wardwell; Mark Mendez – Davis Polk & Wardwell; Barry Gewolb – Davis Polk & Wardwell; Hanbing Zhang – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Paul Lee – Davis Polk & Wardwell; Ann Becchina – Davis Polk & Wardwell; Timothy John Durbin – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Morgan Stanley; JP Morgan Securities;


Author: Ambrogio Visconti